Sign inJoin waitlistJoin the waitlist

Joyce Teng

Program Director of Pediatric Dermatology Fellowship · Stanford Health Care

Credentials: · · · · · ·

History

Pediatric Dermatology Fellowship · Stanford Health Care
Present
Stanford Health Care
Present
Stanford Health Care
Present

University of Colorado Health Science Center (2006) CO
2005–2006
University of Colorado Health Science Center (2006) CO
2003–2006
Dermatology
Vanderbilt University Medical Center
1998–2002
Preliminary or Transitional Year
1997–1998
Memorial Sloan-Kettering Institute
1996–1997
Medical College of Wisconsin
1989–1993
Stanford University
1985–1989

Research

Chemically defined conditions for human iPSC derivation and culture
Nature Methods · 2011 · 1,151 citations
Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a Child
Case report · JAMA Dermatology · 2019 · Last of 5 authors · 118 citations
Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis
Case report · Archives of Dermatology · 2010 · Last of 3 authors · Corresponding · 111 citations

Amy Paller
14 papers
Keith Choate
11 papers
AF
Alexander Fogel
9 papers
RL
Ramrada Lekwuttikarn
8 papers
ES
Eli Sprecher
7 papers
Christopher Bunick
6 papers
Anna Bruckner
5 papers
Dawn Siegel
5 papers
Joanna Tu
5 papers
Kavita Sarin
5 papers
Kerri Rieger
5 papers
LB
Latanya Benjamin
5 papers

Grants

Topical Statin Therapy for Proliferating Infantile Hemangioma
National Institute of Arthritis and Musculoskeletal and Skin Diseases · R61
Contact PI · $302.1K · Stanford University
2026–2029
Vasculata 2024
National Heart, Lung, and Blood Institute · R13
PI · $34.5K · Stanford University
2024–2025
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Food and Drug Administration · R01
Contact PI · $882K · Stanford University
2014–2021

Clinical trials

Topical Simvastatin for Treating Infantile Hemangioma
Principal investigator · Not yet recruiting · Early phase 1
Joyce Teng
2026–2029
Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex
Principal investigator · Not yet recruiting · Phase 2
Stanford University
2026–2028
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Principal investigator · Active not recruiting · Phase 3
Palvella Therapeutics, Inc.
2024–2026
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Principal investigator · Completed · Phase 3
Palvella Therapeutics, Inc.
2021–2023